For those wanting an in-depth review:

Eric Topol: “The GLP-1 and now triple G-Agonists are exceeding expectations as weight loss drugs. Benefits for cardiovascular outcomes, possibly Type 1 diabetes, addiction, and more are reviewed in the latest Ground Truths.” His newsletter also describes the early results of these medications with MASH/NASH with improvement in ~90%.

To get the full review, go to Ground Truths: http://erictopol.substack.com (can sign up to get regular emails on many current medical topics)

Related blog posts:

• Getting over the Stigma of Medicines for Anxiety/Depression and Obesity
• Oral GLP-1 Receptor Agonist for Obesity: Orforglipron
• Another Promising Medication (Retatrutide) for Obesity
• Meds for Obesity: AAP Guidelines